Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization

doi:10.19982/j.issn.1000-6621.20220187

Abstract

Abstract:

The previous guidelines on the application and operational procedure of phenotypic drug susceptibility testing issued by World Health Organization (WHO) are all relevant to the modified L-J medium-based proportion drug susceptibility test (DST), liquid medium DST, and Middle 7H10/7H11 DST; however, the microdilution plate method has never been described in detail. Because of the advantages of the microplate method for DST, and based on the previous research results and application, the WHO first released the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex in April 2022. Here we interprets the background of the document, advantages of microplate DST, drug layout design, issues to be considered in methodology, and implications for relevant work in China, so as to provide the reference for relevant scientific research, medical staffs and manufacturers in China.

Key words: Microbial sensitivity tests, Mycobacterium tuberculosis, Consensus development conferences as topic

CLC Number:

R446.5

XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645. doi: 10.19982/j.issn.1000-6621.20220187

References 6

[1]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: diagnosis-rapid diagnostics for tuberculosis detection. Geneva: World Health Organization, 2020.
[2]	World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization, 2021.
[3]	World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: World Health Organization, 2021.
[4]	World Health Organization. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. Geneva: World Health Organization, 2022.
[5]	Xia H, Song Y, Zheng Y, et al. Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing. Infect Drug Resist, 2022, 15:1345-1352. doi: 10.2147/IDR.S358301. doi: 10.2147/IDR.S358301 URL
[6]	Clinical and Laboratory Standards Institute. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia, Spp., and Other Aerobic Actinomycetes. Wayne: Clinical and Laboratory Standards Institute, 2018.

[1]	LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
[2]	DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679.
[3]	JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726.
[4]	The Joint Tuberculosis Professional Branch of Chinese Antituberculosis Association, The Western China Bone Tuberculosis Union, The North China Union of Bone Tuberculosis. Expert consensus on the diagnosis and treatment of Brucella spondylitis [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 531-538.
[5]	AN Hui-ru, WU Xue-qiong. Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
[6]	CHEN Zhi, LIANG Jian-qin. Expert consensus on nutritional assessment and nutritional support treatment for patients with severe tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 421-432.
[7]	HE Yi-jun, CAO Xue-fang, GAO Lei. Interpretation of the Procedure of tuberculin skin test-interferon-gamma release assay two-step testing [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 438-441.
[8]	DAI Guang-ming, WANG fen, CAO Ting-ming, CHU Hong-qian, HUANG Hai-rong, SUN Zhao-gang. Study on efficiency of Mycobacterium tuberculosis detection by real-time quantitative PCR with different clinical sample types and the improvement by grinding specimen with glass beads [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 450-454.
[9]	SUN Qing, LIAO Xin-lei, WANG Chen-qian, JIANG Guang-lu, DONG Ling-ling, WANG Fen, ZHAO Li-ping, HUANG Hai-rong, WANG Gui-rong. Characterization of rifampin resistance determining region mutations in tuberculosis patients with GeneXpert MTB/RIF positive RNA polymerase β subunit gene mutation [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 349-353.
[10]	TIAN Li, ZHOU Wei, HUANG Xing, WU Xian-wei, ZHANG Hui-yong, LU Zhen-hui, ZHANG Shao-yan. Analysis of gene mutation characteristics of isoniazid-resistant Mycobacterium tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 354-361.
[11]	MA Yan, LU Wei, GAO Lei, CHU Nai-hui, ZHOU Lin, CHENG Shi-ming. To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 209-214.
[12]	LI Dong-shuo, WANG Bin, LU Yu, XU Jian. Study of expression and function of Mycobacterium tuberculosis membrane protein MmpL5-MmpS5 [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 227-233.
[13]	FAN Ru, LI Xiao-fei. Research progress of molecular biology detection technology for tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 294-298.
[14]	SUN Zhao-gang. Attention should be paid to the research and development of Mycobacterium tuberculosis antigen detection technology [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 120-124.
[15]	WANG Shao-hua, ZHAO Guo-lian, WANG Pei, TAN Xiao-wen, CUI Xiao-li, KANG Lei, DANG Li-yun. Analysis of inconsistency between genotypic and phenotypic results of Mycobacterium tuberculosis rifampicin susceptibility test [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 169-173.